Synthesis of 5(S)-Methyl-L-Proline Containing Peptidomimetic Compounds
and their In Vitro Evaluation for Dipeptidyl Peptidase-4 Inhibition

Anuradha   K.   Gajjar; Chirag   D.   Pathak

doi:10.2174/1570180819666220103124013

Abstract

Background: Type 2 diabetes mellitus (T2DM), which is the epidemic of the 21st century, has affected millions of people worldwide. Traditional methods available for the treatment are associated with various side effects. Among the newer therapies, DPP-4 (Dipeptidyl peptidase-4) inhibition has been a promising therapy for the past decade with the scope of further development, especially in peptidomimetics.

Objective: 5(S)-methyl-L-proline containing peptidomimetic compounds were designed in the previous work. The designed compounds were synthesized and characterized by spectral methods, such as mass spectrometry, ¹H NMR, and ¹³C NMR (Nuclear magnetic resonance) spectroscopy. The purity of the final compounds was determined by high-performance liquid chromatography (HPLC). The synthesized compounds were in vitro evaluated for their DPP-4 inhibitory activity.

Methods: Compounds were peptide in nature and were synthesized using the conventional synthesis approach, where peptide synthesis was done using an acid-amine coupling reagent. They were evaluated through fluorimetric enzyme-based assay using a DPP-4 inhibitor screening kit. Moreover, the CLARIOstar microplate reader instrument was used to measure fluorescence.

Results: 5(S)-methyl-L-proline containing 13 compounds were synthesized. All of them were characterized for structural integrity using spectral methods. They had HPLC purity of more than 95% and were evaluated for DPP-4 inhibition. Compounds 1, 7, 10, 11, 14 and 17 were found to have good inhibition than others. These compounds were further evaluated at different concentrations to develop a linear correlation coefficient (R²).

Conclusion: Six compounds were found to have good DPP-4 inhibition, hence it further opens the possibility of developing DPP-4 inhibitor-containing 5(S)-methyl-L-proline.

Keywords: T2DM, DPP-4, DPP-4 inhibitor, peptidomimetics, in vitro assay, fluorimetric enzyme-based assay.

« Previous

Graphical Abstract

[1] 
Soe, K.; Sacerdote, A.; Karam, J.; Bahtiyar, G. Management of type 2 diabetes mellitus in the elderly. Maturitas,  2011, 70(2), 151-159.
[http://dx.doi.org/10.1016/j.maturitas.2011.07.006] [PMID:  21890292] 
[2] 
Zheng, Y.; Ley, S.H.; Hu, F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol.,  2018, 14(2), 88-98.
[http://dx.doi.org/10.1038/nrendo.2017.151] [PMID:  29219149] 
[3] 
Moore, B. On the treatment of diabetus mellitus by acid extract of duodenal mucous membrane. Biochem. J.,  1906, 1(1), 28-38.
[http://dx.doi.org/10.1042/bj0010028] [PMID:  16742013] 
[4] 
Doupis, J.; Veves, A. DPP4 inhibitors: A new approach in diabetes treatment. Adv. Ther.,  2008, 25(7), 627-643.
[http://dx.doi.org/10.1007/s12325-008-0076-1] [PMID:  18641927] 
[5] 
Li, N.; Wang, L-J.; Jiang, B.; Li, X-Q.; Guo, C-L.; Guo, S-J.; Shi, D-Y. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Eur. J. Med. Chem.,  2018, 151, 145-157.
[http://dx.doi.org/10.1016/j.ejmech.2018.03.041] [PMID:  29609120] 
[6] 
Creutzfeldt, W. The incretin concept today. Diabetologia,  1979, 16(2), 75-85.
[http://dx.doi.org/10.1007/BF01225454] [PMID:  32119] 
[7] 
Nauck, M.; Stöckmann, F.; Ebert, R.; Creutzfeldt, W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia,  1986, 29(1), 46-52.
[http://dx.doi.org/10.1007/BF02427280] [PMID:  3514343] 
[8] 
Creutzfeldt, W.; Ebert, R. New developments in the incretin concept. Diabetologia,  1985, 28(8), 565-573.
[http://dx.doi.org/10.1007/BF00281990] [PMID:  3902545] 
[9] 
Dupre, J.; Ross, S.A.; Watson, D.; Brown, J.C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab.,  1973, 37(5), 826-828.
[http://dx.doi.org/10.1210/jcem-37-5-826] [PMID:  4749457] 
[10] 
Kreymann, B.; Williams, G.; Ghatei, M.A.; Bloom, S.R. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet,  1987, 2(8571), 1300-1304.
[http://dx.doi.org/10.1016/S0140-6736(87)91194-9] [PMID:  2890903] 
[11] 
Gutniak, M.; Orskov, C.; Holst, J.J.; Ahrén, B.; Efendić, S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med.,  1992, 326(20), 1316-1322.
[http://dx.doi.org/10.1056/NEJM199205143262003] [PMID:  1348845] 
[12] 
Qualmann, C.; Nauck, M.A.; Holst, J.J.; Orskov, C.; Creutzfeldt, W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol.,  1995, 32(1), 13-16.
[http://dx.doi.org/10.1007/BF00581038] [PMID:  7612912] 
[13] 
Nauck, M.A.; Wollschläger, D.; Werner, J.; Holst, J.J.; Orskov, C.; Creutzfeldt, W.; Willms, B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia,  1996, 39(12), 1546-1553.
[http://dx.doi.org/10.1007/s001250050613] [PMID:  8960841] 
[14] 
Nauck, M.A. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm. Metab. Res.,  2004, 36(11-12), 852-858.
[http://dx.doi.org/10.1055/s-2004-826175] [PMID:  15655719] 
[15] 
Nauck, M.A.; Meier, J.J. Incretin hormones: Their role in health and disease. Diabetes Obes. Metab.,  2018, 20(Suppl. 1), 5-21.
[http://dx.doi.org/10.1111/dom.13129] [PMID:  29364588] 
[16] 
Drucker, D.J.; Nauck, M.A. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet,  2006, 368(9548), 1696-1705.
[http://dx.doi.org/10.1016/S0140-6736(06)69705-5] [PMID:  17098089] 
[17] 
Mentlein, R.; Gallwitz, B.; Schmidt, W.E.; Dipeptidyl-Peptidase, I.V. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem.,  1993, 214(3), 829-835.
[http://dx.doi.org/10.1111/j.1432-1033.1993.tb17986.x] [PMID:  8100523] 
[18] 
Pratley, R.E.; Salsali, A. Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin.,  2007, 23(4), 919-931.
[http://dx.doi.org/10.1185/030079906X162746] [PMID:  17407649] 
[19] 
Misumi, Y.; Hayashi, Y.; Arakawa, F.; Ikehara, Y. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface. Biochim. Biophys. Acta,  1992, 1131(3), 333-336.
[http://dx.doi.org/10.1016/0167-4781(92)90036-Y] [PMID:  1352704] 
[20] 
Thornberry, N.A.; Gallwitz, B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract. Res. Clin. Endocrinol. Metab.,  2009, 23(4), 479-486.
[http://dx.doi.org/10.1016/j.beem.2009.03.004] [PMID:  19748065] 
[21] 
Ahrén, B. DPP-4 inhibition and the path to clinical proof. Front. Endocrinol. (Lausanne),  2019, 10, 376.
[http://dx.doi.org/10.3389/fendo.2019.00376] [PMID:  31275243] 
[22] 
Xu, J.; Wei, L.; Mathvink, R.; Edmondson, S.D.; Mastracchio, A.; Eiermann, G.J.; He, H.; Leone, J.F.; Leiting, B.; Lyons, K.A.; Marsilio, F.; Patel, R.A.; Petrov, A.; Wu, J.K.; Thornberry, N.A.; Weber, A.E. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors. Bioorg. Med. Chem. Lett.,  2006, 16(5), 1346-1349.
[http://dx.doi.org/10.1016/j.bmcl.2005.11.052] [PMID:  16332437] 
[23] 
Pei, Z.; Li, X.; von Geldern, T.W.; Madar, D.J.; Longenecker, K.; Yong, H.; Lubben, T.H.; Stewart, K.D.; Zinker, B.A.; Backes, B.J.; Judd, A.S.; Mulhern, M.; Ballaron, S.J.; Stashko, M.A.; Mika, A.K.; Beno, D.W.A.; Reinhart, G.A.; Fryer, R.M.; Preusser, L.C.; Kempf-Grote, A.J.; Sham, H.L.; Trevillyan, J.M. Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifle oromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)meth anone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem.,  2006, 49(22), 6439-6442.
[http://dx.doi.org/10.1021/jm060955d] [PMID:  17064063] 
[24] 
Augeri, D.J.; Robl, J.A.; Betebenner, D.A.; Magnin, D.R.; Khanna, A.; Robertson, J.G.; Wang, A.; Simpkins, L.M.; Taunk, P.; Huang, Q.; Han, S-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G.E.; Egan, D.M.; Marcinkeviciene, J.; Chang, S.Y.; Biller, S.A.; Kirby, M.S.; Parker, R.A.; Hamann, L.G. Discovery and preclinical profile of Saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem.,  2005, 48(15), 5025-5037.
[http://dx.doi.org/10.1021/jm050261p] [PMID:  16033281] 
[25] 
Del Prato, S.; Barnett, A.H.; Huisman, H.; Neubacher, D.; Woerle, H-J.; Dugi, K.A. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes. Metab.,  2011, 13(3), 258-267.
[http://dx.doi.org/10.1111/j.1463-1326.2010.01350.x] [PMID:  21205122] 
[26] 
Feng, J.; Zhang, Z.; Wallace, M.B.; Stafford, J.A.; Kaldor, S.W.; Kassel, D.B.; Navre, M.; Shi, L.; Skene, R.J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D.R.; Gwaltney, S.L., II Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem.,  2007, 50(10), 2297-2300.
[http://dx.doi.org/10.1021/jm070104l] [PMID:  17441705] 
[27] 
Kim, S-H.; Lee, S-H.; Yim, H-J. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: First new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch. Pharm. Res.,  2013, 36(10), 1185-1188.
[http://dx.doi.org/10.1007/s12272-013-0171-x] [PMID:  23771499] 
[28] 
Kato, N.; Oka, M.; Murase, T.; Yoshida, M.; Sakairi, M.; Yamashita, S.; Yasuda, Y.; Yoshikawa, A.; Hayashi, Y.; Makino, M.; Takeda, M.; Mirensha, Y.; Kakigami, T. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-Cyanopyrrolidin-1-Yl]-2-Oxoethyl}amino)-2-Methylpropyl]-2-Methylpyrazolo[1,5-a]Pyrimidine-6-Carboxamide Hydrochloride (Anagliptin Hydrochloride Salt) as a potent and selective DPP-IV inhibitor. Bioorg. Med. Chem.,  2011, 19(23), 7221-7227.
[http://dx.doi.org/10.1016/j.bmc.2011.09.043] [PMID:  22019046] 
[29] 
Yoshida, T.; Akahoshi, F.; Sakashita, H.; Kitajima, H.; Nakamura, M.; Sonda, S.; Takeuchi, M.; Tanaka, Y.; Ueda, N.; Sekiguchi, S.; Ishige, T.; Shima, K.; Nabeno, M.; Abe, Y.; Anabuki, J.; Soejima, A.; Yoshida, K.; Takashina, Y.; Ishii, S.; Kiuchi, S.; Fukuda, S.; Tsutsumiuchi, R.; Kosaka, K.; Murozono, T.; Nakamaru, Y.; Utsumi, H.; Masutomi, N.; Kishida, H.; Miyaguchi, I.; Hayashi, Y. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem.,  2012, 20(19), 5705-5719.
[http://dx.doi.org/10.1016/j.bmc.2012.08.012] [PMID:  22959556] 
[30] 
Grimshaw, C.E.; Jennings, A.; Kamran, R.; Ueno, H.; Nishigaki, N.; Kosaka, T.; Tani, A.; Sano, H.; Kinugawa, Y.; Koumura, E.; Shi, L.; Takeuchi, K. Trelagliptin (SYR-472, Zafatek), novel once-weekly treatment for type 2 diabetes, inhibits Dipeptidyl Peptidase-4 (DPP-4) via a non-covalent mechanism. PLoS One,  2016, 11(6)e0157509
[http://dx.doi.org/10.1371/journal.pone.0157509] [PMID:  27328054] 
[31] 
Biftu, T.; Sinha-Roy, R.; Chen, P.; Qian, X.; Feng, D.; Kuethe, J.T.; Scapin, G.; Gao, Y.D.; Yan, Y.; Krueger, D.; Bak, A.; Eiermann, G.; He, J.; Cox, J.; Hicks, J.; Lyons, K.; He, H.; Salituro, G.; Tong, S.; Patel, S.; Doss, G.; Petrov, A.; Wu, J.; Xu, S.S.; Sewall, C.; Zhang, X.; Zhang, B.; Thornberry, N.A.; Weber, A.E. Omarigliptin (MK-3102): A novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J. Med. Chem.,  2014, 57(8), 3205-3212.
[http://dx.doi.org/10.1021/jm401992e] [PMID:  24660890] 
[32] 
Tella, S.H.; Rendell, M.S. DPP-4 inhibitors: Focus on safety. Expert Opin. Drug Saf.,  2015, 14(1), 127-140.
[http://dx.doi.org/10.1517/14740338.2015.977863] [PMID:  25488788] 
[33] 
Scheen, A.J. DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes Metab.,  2012, 38(2), 89-101.
[http://dx.doi.org/10.1016/j.diabet.2011.11.001] [PMID:  22197148] 
[34] 
Gajjar, A.K.; Pathak, C.D. Structure-based de novo design and docking studies of 5(s)-methyl-l-proline containing peptidomimetic compounds as dipeptidyl peptidase-4 inhibitors. Curr. Drug Discov. Technol., 2021. [Epub ahead of print]
[35] 
Rajan, S.T.; Eswaraiah, S.; Reddy, GV.R. Process for the preparation of DPP-IV inhibitor. WO Patent, 2013111158 A2 2013.

Rights & Permissions Print Cite

Article Metrics

14

1

Explore Articles

Open Access

Open Access Articles

DOI https://dx.doi.org/10.2174/1570180819666220103124013	Print ISSN 1570-1808
Publisher Name Bentham Science Publisher	Online ISSN 1875-628X

Letters in Drug Design & Discovery

Synthesis of 5(S)-Methyl-L-Proline Containing Peptidomimetic Compounds and their In Vitro Evaluation for Dipeptidyl Peptidase-4 Inhibition

Abstract Play Pause

Graphical Abstract

Abstract